- Lenacapavir is a long-lasting injection for prevention.
- It helps stop HIV entering the body.
- The shot is given every six months.
- Trials show the injection works very well.
- If it is affordable, many more people can use it.
- Health services must keep the supply steady.
- People need to return for injections on time.
- Many African areas have high HIV rates.
- Countries may offer different prevention choices.
- The shot could reduce many new infections.
Difficult words
- injection — a medicine given with a needleinjections
- prevention — action to stop illness or disease
- affordable — not too expensive for many people
- supply — a stock of medicine or goods
- infection — a disease caused by germs in bodyinfections
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you return for injections on time?
- Do you prefer a shot or a pill for prevention?
- Is a steady supply of medicine important where you live?
Related articles
Genes linked to chronic kidney disease
Researchers led by Alejandro Chade at the University of Missouri studied genes involved in chronic kidney disease using animal models. They found genes linked to kidney damage; silencing one gene lowered fibrosis. The team will map and test gene activity.
Cell transplant may help heart after spinal cord injury
Researchers tested transplanting immature nerve cells into spinal cord injuries in rats. The transplants improved nerve control of circulation — stabilizing resting blood pressure and lowering heart rate — but hormonal responses after injury still rose.
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
